Please login to the form below

Not currently logged in
Email:
Password:

AZ's novel cancer drug to be trialled

Cancer Research UK and AstraZeneca are to take AZD-3965 – a first-of-its-kind drug to potentially treat a range of cancers – into clinical trial

Cancer Research UK and Cancer Research Technology (CRT) – the charity's development and commercialisation arm - have reached an agreement with AstraZeneca (AZ) to take compound AZD-3965 – a first-of-its-kind experimental drug to potentially treat a range of cancers - into clinical trial.

AZD-3965 targets the monocarboxylate transporter 1 (MCT1) which is essential in cell metabolism. Blocking this transporter limits cancer cells' ability to generate energy, and decreases their ability to survive.

It is the sixth treatment to enter Cancer Research UK's Clinical Development Partnerships (CDP) scheme.

Les Hughes, global vice-president of cancer research at AZ, said: "Working with CRT will enable a compound with a very exciting mechanism to be evaluated in patients using Cancer Research UK's extensive clinical network. We look forward to this collaboration adding a new dimension to AstraZeneca's pipeline which contains a number of promising candidates already in development."

CDP is a joint initiative between Cancer Research UK's Drug Development Office and CRT, to progress promising anti-cancer agents that pharmaceutical companies do not have the resources to progress through early phase clinical trials.

Dr Ian Walker, licensing manager for clinical partnerships at Cancer Research Technology, said: "It is fantastic to see a drug from our CDP programme progressing toward a clinical trial to be tested as a potential new treatment for cancer patients.

"This clinical trial simply would not have been possible without the CDP initiative and it demonstrates how Cancer Research UK and Cancer Research Technology can work with industry to develop anti-cancer drugs that would otherwise remain on companies' shelves."

Cancer Research UK will fund the phase I/IIa clinical trial of up to 60 patients to start in 2011. The lead clinical trial centre will be Newcastle's Cancer Research UK Experimental Cancer Medicine Centre Network, led by Professor Ruth Plummer.

Under the terms of the agreement, AZ can decide if they wish to develop the drug further based on the clinical trial data results at the end of the phase I/IIa trial. If it chooses not to, the rights will be given to CRT to secure an alternative partner and ensure the drug has every possible chance of reaching patients. In either case, the charity will receive a share of any future revenues generated by the drug.

14th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics